diclofenac has been researched along with cox 189 in 141 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 92 (65.25) | 29.6817 |
| 2010's | 46 (32.62) | 24.3611 |
| 2020's | 3 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Blobaum, AL; Marnett, LJ | 2 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bajorath, J; Stumpfe, D | 1 |
| Banerjee, S; Marnett, LJ; Valk, PL; Windsor, MA; Xu, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Frölich, JC; Stichtenoth, DO | 1 |
| Branson, J; Ford, M; Kellett, N; Mair, S; Milosavljev, S; Rordorf, C; Scott, G | 1 |
| Bevan, S; Courade, JP; Dawson, J; Fox, A; Glatt, M; Gonzalez, I; Medhurst, S; Urban, L | 1 |
| Laurent, A; Milosavljev, S; Rordorf, C; Scott, G; Yeh, CM; Yih, L | 1 |
| Atherton, C; Bebb, J; Bonner, J; Branson, J; Brough, J; Burdsall, J; Cunliffe, R; Hawkey, CJ; Jones, J; McKaig, B; Rordorf, C; Scott, G; Stevenson, D | 1 |
| Adami, S; Berenbaum, F; Bliddal, H; Gimona, A; Lee, A; Moore, A; Navarro, F; Poor, G; Reginster, JY; Robinson, J; Tannenbaum, H; Uebelhart, D; Zacher, J | 1 |
| Langholff, W; Milosavljev, S; Rordorf, C; Scott, G; Shenouda, M; Vinluan Reynolds, C | 1 |
| Bonner, J; Dickson, J; Gu, H; Mangold, JB; Rodriguez, LC; Rordorf, C | 1 |
| Fricke, J; Jayawardene, S; Kellstein, D; Ott, D | 1 |
| Fricke, JR; Jayawardene, S; Kellstein, D; Zelenakas, K | 1 |
| Huff, JP; Kalbag, J; Looby, M; Milosavljev, S; Reynolds, C; Rordorf, C; Ruff, DA; Scott, G; Weaver, M | 1 |
| Caldwell, J; Elder, C; Kalbag, J; Leese, P; Milosavljev, S; Rordorf, C; Scott, G; Wang, Y | 1 |
| Gimona, A; Hawkey, C; Kivitz, AJ; Nayiager, S; Schimansky, T; Thurston, HJ | 1 |
| Bitner, M; Gao, J; Hatfield, C; Kattenhorn, J; Kellstein, D | 1 |
| Kalbag, J; Lasseter, K; Milosavljev, S; Oberstein, S; Rordorf, C; Yeh, CM | 1 |
| Ehrsam, E; Farkouh, M; Gitton, X; Hawkey, CJ; Huels, J; Richardson, P | 1 |
| Mysler, E | 1 |
| Beier, J; Geusens, P; Gitton, X; Hasler, P; Moore, A; Patel, SK; Poór, G; Schnitzer, TJ; Senftleber, I; Sloan, VS | 1 |
| Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P | 1 |
| Branson, JM; Chales, GH; Hartmann, SN; Juvin, RR; Lafforgue, P; Le Parc, JM; Meyer, OC; Milosavljev, S; Rordorf, CM; Tavernier, CG | 1 |
| Curran, MP; Lyseng-Williamson, KA | 1 |
| Summerton, N | 1 |
| Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH | 1 |
| Alten, R; Geusens, P; Kralidis, G; Krammer, G; Richardson, P; Rovensky, J; Sloan, VS | 1 |
| Berry, C; Dawson, J; Du, Z; Esser, R; Fox, A; Fujimoto, RA; Haston, W; Kimble, EF; Koehler, J; Marshall, PJ; Peppard, J; Quadros, E; Quintavalla, J; Toscano, K; Urban, L; van Duzer, J; Zhang, X; Zhou, S | 1 |
| Doggrell, SA | 1 |
| Beaulieu, A; Dutta, D; Paster, Z; Sheldon, E; Sloan, VS; Yu, S | 1 |
| Cramer, JA; Esser, RE; Georgieva, A; Maniara, W; Miserendino-Molteni, R; Porter, W; Ramos, L; Sharr, M; Zhang, X; Zhuang, S | 1 |
| Castañeda-Hernández, G; Granados-Soto, V; Lozano-Cuenca, J | 1 |
| Gitton, X; Jayawardene, S; Schnitzer, TJ; Sloan, VS | 1 |
| Bannwarth, B; Berenbaum, F | 2 |
| Brzosko, M; Kopsa, P; Kreisse, A; Lehmann, R; Litschig, S; Nischik, R; Sloan, VS; Thurston, H | 1 |
| Hochberg, MC | 1 |
| Dutta, D; Fleischmann, R; Maldonado-Cocco, J; Sheldon, E; Sloan, VS; Yu, S | 1 |
| Branson, J; Guillaume, M; Jermany, J; Rordorf, C; Schmouder, R | 1 |
| Packman, B; Packman, E; Thurston, H; Tseng, L | 1 |
| Amann, R; Grill, M; Peskar, BA; Schuligoi, R | 1 |
| Ehrsam, E; Garaud, JJ; Gitton, X; Hoexter, G; Krammer, G; Matchaba, P; Mellein, B; Olson, M; Orloff, J; Sloan, VS | 1 |
| Chan, VW; Clark, AJ; Davis, JC; Jayawardene, S; Kellstein, D; Wolf, RS | 1 |
| Goldstein, JL; Rosenberg, JA | 1 |
| Ciulla, TA; Cornell, TL; Criswell, MH; Danis, RP; Hu, W; Lambrou, GN; Ottlecz, A | 1 |
| Choi, L; Mangold, JB; Marshall, P; Rordorf, CM | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Gitton, X; Hawkey, CJ; Hoexter, G; Richard, D; Weinstein, WM | 1 |
| Burger, KJ; Fashola, TO; Krehan, G; Maeumbaed, R; Runge, H; Schell, E; Schlüter, P; Thurston, HJ; Trechsel, U; Wittenberg, RH | 1 |
| Geisslinger, G; Manderscheid, C; Niederberger, E | 1 |
| Brune, K; Cheremina, O; Hinz, B | 1 |
| Marwali, MR; Mehta, JL | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Deray, G; Héloire, F; Valat, JP | 1 |
| Dougados, M; Gitton, X; Moore, A; Yu, S | 1 |
| Barkin, R; Buvanendran, A | 1 |
| Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW | 1 |
| Fu, YF; Ni, J; Ren, J; Shu, YY; Tang, W; Wang, H; Wang, MW; Yang, YF; Zhong, XG; Zhu, YN; Zuo, JP | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Derbot, J; Jung, T; Krammer, G; Kreiss, A; Litschig, S; Mysler, E; Tate, GA; Thurston, H; Willburger, RE | 1 |
| Castañeda-Hernández, G; Ortiz, MI | 1 |
| Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM | 1 |
| Birkenmeier, K; Felix, SB; Janke, I; Krieg, T; Labitzke, C; Landsberger, M; Prange, T; Schunck, WH; Stangl, V; Staudt, A; Trimpert, C | 1 |
| Baraf, HS | 1 |
| Hunt, RH; Yuan, Y | 1 |
| Burton, B | 2 |
| Davis, N; Fricke, J; Krammer, G; Yu, V | 1 |
| Derry, S; Moore, RA; Roy, YM | 2 |
| Duh, D; Vandevijver, A | 1 |
| Ambrosio, E; Ambrosio, M; Andersson, M; Buccellati, C; Capra, V; Dahlén, B; Dahlén, SE; Ezinga, M; Folco, GC; Larsson, AK; Låstbom, L; Rovati, GE; Ryrfeldt, A; Sala, A; Selg, E | 1 |
| Brune, K | 1 |
| Baillie, TA; Braun, MP; Dean, DC; Doss, GA; Li, Y; Slatter, JG; Stearns, RA; Tang, W; Zhang, Z | 1 |
| Klotz, U; Shi, S | 1 |
| Chaves, MH; Cunha, GM; Holanda Pinto, SA; Pinto, LM; Rao, VS; Santos, FA | 1 |
| Hawkey, CJ; Krammer, G; Murphy, V; Rebuli, R; Richard, D; Stricker, K; Weinstein, WM | 1 |
| Albert, J; Arulmani, U; Bolten, W; Ell, C; Fortun, P; Hawkey, CJ; Hugot, JL; Keuchel, M; Krammer, G; McAlindon, M; Rebuli, R; Schumann, S; Shonde, A; Simon, B; Toth, E; Yu, V | 1 |
| Fleischmann, R; Notter, M; Patel, NP; Reginster, JY; Sallstig, P; Tannenbaum, H | 1 |
| Barton, S; Daniels, S; Gitton, X; Stricker, K; Zhou, W | 1 |
| Hao, JQ; Li, Q; Shen, YX; Sun, GY; Xu, SP | 1 |
| Krammer, G; Lheritier, K; Littlejohn, TW; MacDonald, TM; Rebuli, R; Reginster, JY; Richard, D | 1 |
| Celikel, S; Isik, SR; Kalyoncu, AF; Karakaya, G | 1 |
| Chesebro, JH; Farkouh, ME; Gitton, X; Jeger, R; Kirshner, H; Krammer, G; Matchaba, P; Mellein, B; Ruland, S; Sallstig, P; Stricker, K; Verheugt, FW | 1 |
| Krammer, G; Stricker, K; Yu, S | 1 |
| Dalvie, D; Kang, P; Renner, M; Smith, E | 1 |
| Besz, D; Brune, K; Cheremina, O; Hinz, B; Renner, B; Zolk, O | 1 |
| Adekunle, F; Andrews, C; Ellis, G; Kinch, H; Kyle, C; Zachariah, J | 1 |
| Capuano, A; De Corato, A; Dello Russo, C; Navarra, P; Treglia, M; Tringali, G | 1 |
| Bernardi, LS; Mendes, C; Oliveira, PR; Sangoi, MS; Silva, MA | 1 |
| Aita, K; Katada, Y; Kimura, H; Kuge, Y; Obokata, N; Saji, H; Seki, K; Sugimoto, Y; Tamaki, N; Temma, T | 1 |
| de Oliveira Costa, H; Franco, M; Miszputen, SJ; Oshima, CT; Paiotti, AP; Ribeiro, DA | 1 |
| Castañeda-Hernández, G; Ortiz, MI; Salazar-Morales, UE; Trocóniz, IF; Vásquez-Bahena, DA | 1 |
| Caran, JZ; Kruel, CD; Lovison, RC; Maioli, DT; Molon, V | 1 |
| Capra, V; Dahlén, SE; Folco, G; Rovati, GE; Sala, A | 1 |
| Chakraborti, AK; Garg, SK; Jadhavar, PS; Kumar, R; Motiwala, HF | 1 |
| de Sousa, VP; Moreira, TS; Pierre, MB | 2 |
| Krammer, G; Lheritier, K; MacDonald, TM; Richard, D | 1 |
| Elliott, WJ | 1 |
| Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM | 1 |
| Colbatzky, F; Göggel, R; Nickolaus, P; Peter, D | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| de Almeida, JM; Fernandes, LA; Garcia, VG; Takano, RY; Theodoro, LH | 1 |
| Campos, ML; Chelucci, R; Chiquetto, R; Chung, MC; dos Santos, JL; Peccinini, RG | 1 |
| Fontana, RJ; Tujios, S | 1 |
| Bruno, MA; Bruno, MB; da Motta, AF; Krymchantowski, AV; Mucha, JN | 1 |
| Dattani, ID; Maxwell, T; Moore, A; Rebuli, R; Sallstig, P; Schneider, H; Schnitzer, TJ; Seriolo, B; Tseng, L | 1 |
| Bernardi, LS; Oliveira, PR; Sangoi, MS; Wrasse-Sangoi, M | 1 |
| Riera, R; Saconato, H; Silva, RC | 1 |
| Ghiculescu, RA; Lampe, G; Macdonald, GA; Pillans, PI; Wilson, R; Wong, R | 1 |
| Franco, M; Marchi, P; Miszputen, SJ; Neto, RA; Oshima, CT; Paiotti, AP; Ribeiro, DA; Silva, RM | 1 |
| Chitturi, S; Farrell, GC | 1 |
| Macdonald, TM; Mackenzie, IS; Wei, L | 1 |
| Bertinaria, M; Buccellati, C; Capra, V; Cena, C; Fruttero, R; Gasco, A; Hoxha, M; Lazzarato, L; Rolando, B; Rovati, GE; Sala, A; Shaikh, MA | 1 |
| Castañeda-Hernández, G; Jiménez-Andrade, JM; Ortiz, MI; Trocóniz, IF; Vásquez-Bahena, D; Vélez de Mendizábal, N | 1 |
| Hawkins, MT; Lewis, JH | 1 |
| Harirforoosh, S; Pettit, WL; Wyatt, JE | 1 |
| Barbieri, KP; Bosquesi, PL; Campos, ML; Chelucci, RC; Chin, CM; de Castro Souto, PC; Matsubara, MH; Moreira, V; Peccinini, RG; Santos, JL; Teixeira, C | 1 |
| Casati, MZ; Nociti, FH; Peres, MF; Ribeiro, FV; Ruiz, KG; Sallum, EA | 1 |
| Kaniwa, N; Saito, Y | 1 |
| Bell, CJ; Eckstein, RP; Fok, KC; Jones, BE; Read, RB | 1 |
| Bartzatt, R | 1 |
| Angioni, C; Felden, L; Ferreiros, N; Geisslinger, G; Lötsch, J; Schreiber, Y; von Hentig, N; Walter, C | 1 |
| Honjo, H; Nabekura, T; Uwai, Y | 1 |
| Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
| Anstaett, P; Ferrari, S; Gasser, G; Pierroz, V | 1 |
| Bertinaria, M; Buccellati, C; Capra, V; Carnevali, S; Cena, C; Fruttero, R; Garella, D; Hoxha, M; Rolando, B; Rovati, GE; Sala, A | 1 |
| Hansen, SH; Skonberg, C; Syed, M | 1 |
| D Wilson, I; P Dickie, A; Riley, R; Schreiter, K; Wehr, R; Wilson, CE | 1 |
| Aklillu, E; Makonnen, E; Petros, Z | 1 |
| Blank, C; Brummer, C; Bruss, C; Faerber, S; Haferkamp, S; Herr, W; Kreutz, M; Lacroix, R; Renner, K | 1 |
| Cui, Y; Jiao, W; Wu, G; Wu, H; Zhang, X; Zhao, X | 1 |
| Alvarez, AM; DeOcesano-Pereira, C; Moreira, V; Teixeira, C | 1 |
| Liu, Q; Sun, J; Zhang, L | 1 |
31 review(s) available for diclofenac and cox 189
| Article | Year |
|---|---|
Structural and functional basis of cyclooxygenase inhibition.
Topics: Animals; Cardiovascular System; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Kinetics; Models, Molecular; Protein Conformation; Risk Assessment | 2007 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The second generation of COX-2 inhibitors: what advantages do the newest offer?
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Interactions; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfonamides; Sulfones | 2003 |
Lumiracoxib (Prexige): a new selective COX-2 inhibitor.
Topics: Acute Disease; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Evaluation; Drug Interactions; Gastrointestinal Diseases; Humans; Isoenzymes; Membrane Proteins; Organic Chemicals; Pain; Prostaglandin-Endoperoxide Synthases | 2004 |
The safety of lumiracoxib when used in the treatment of arthritis.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Organic Chemicals; Stomach Ulcer | 2005 |
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Dysmenorrhea; Female; Gastrointestinal Hemorrhage; Humans; Osteoarthritis; Pain, Postoperative; Randomized Controlled Trials as Topic | 2005 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Databases, Factual; Diclofenac; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Randomized Controlled Trials as Topic | 2005 |
Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Kidney Diseases; Liver Diseases; Organic Chemicals; Osteoarthritis | 2005 |
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Randomized Controlled Trials as Topic | 2006 |
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides | 2007 |
Lumiracoxib.
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Drug Interactions; Humans | 2007 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Lumiracoxib in the management of osteoarthritis and acute pain.
Topics: Acute Disease; Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Humans; Osteoarthritis; Pain; Peptic Ulcer; Risk Assessment; Treatment Outcome | 2007 |
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones | 2007 |
Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Interactions; Endoscopy, Gastrointestinal; Etoricoxib; Humans; Occult Blood; Patient Selection; Peptic Ulcer; Peptic Ulcer Hemorrhage; Pyridines; Risk Assessment; Risk Factors; Sulfones | 2007 |
Single dose oral lumiracoxib for postoperative pain.
Topics: Administration, Oral; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Pain, Postoperative; Randomized Controlled Trials as Topic | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2008 |
Progress in COX-2 inhibitors: a journey so far.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Heterocyclic Compounds; Lactones; Models, Molecular; Sulfones | 2010 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Single dose oral lumiracoxib for postoperative pain in adults.
Topics: Acute Disease; Administration, Oral; Adult; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Pain, Postoperative; Randomized Controlled Trials as Topic; Time Factors | 2010 |
Mechanisms of drug-induced liver injury: from bedside to bench.
Topics: Acetaminophen; Animals; Azetidines; Benzylamines; Chemical and Drug Induced Liver Injury; Diclofenac; Floxacillin; Humans; Inactivation, Metabolic; Mice; Mitochondria, Liver; Models, Animal | 2011 |
Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials.
Topics: Acute Pain; Anti-Inflammatory Agents; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Pain, Postoperative; Randomized Controlled Trials as Topic; Risk Assessment; Toothache | 2011 |
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Male; Middle Aged; Osteoarthritis | 2013 |
Latest advances in predicting DILI in human subjects: focus on biomarkers.
Topics: Antitubercular Agents; Apolipoproteins E; Arylamine N-Acetyltransferase; Azetidines; Benzylamines; Biomarkers; Chemical and Drug Induced Liver Injury; Diclofenac; Floxacillin; HLA-B Antigens; Humans; Liver; Metabolomics; Pharmacogenetics; Polymorphism, Genetic; Proteomics; Risk Factors | 2012 |
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides | 2012 |
Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Topics: Alleles; Allopurinol; Amoxicillin-Potassium Clavulanate Combination; Azetidines; Benzylamines; Carbamazepine; Chemical and Drug Induced Liver Injury; Diclofenac; Dideoxynucleosides; Drug Hypersensitivity; Floxacillin; Genetic Markers; HLA Antigens; HLA-A Antigens; HLA-B Antigens; HLA-DQ alpha-Chains; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Skin; Stevens-Johnson Syndrome; Ticlopidine | 2013 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
45 trial(s) available for diclofenac and cox 189
| Article | Year |
|---|---|
Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
Topics: Adolescent; Adult; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Endoscopy, Gastrointestinal; Gastrointestinal Diseases; Humans; Intestinal Mucosa; Isoenzymes; Male; Membrane Proteins; Middle Aged; Naproxen; Organic Chemicals; Pilot Projects; Prostaglandin-Endoperoxide Synthases; Thromboxanes | 2003 |
Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects.
Topics: Adult; Antifungal Agents; Area Under Curve; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Interactions; Female; Fluconazole; Humans; Isoenzymes; Male; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Thromboxane B2 | 2004 |
Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.
Topics: Adolescent; Adult; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Digestive System; Double-Blind Method; Female; Gastroscopy; Humans; Intestinal Absorption; Isoenzymes; Male; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Safety | 2004 |
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoenzymes; Logistic Models; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2004 |
Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.
Topics: Adolescent; Adult; Aluminum Hydroxide; Antacids; Area Under Curve; Cross-Over Studies; Cyclooxygenase 2; Diclofenac; Drug Combinations; Enzyme Inhibitors; Female; Humans; Isoenzymes; Magnesium Hydroxide; Male; Membrane Proteins; Middle Aged; Omeprazole; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors | 2004 |
Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Lactones; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction; Treatment Outcome | 2004 |
Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain.
Topics: Adolescent; Adult; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Ibuprofen; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pilot Projects; Tooth Extraction; Treatment Outcome | 2004 |
Pharmacokinetics of lumiracoxib in plasma and synovial fluid.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofenac; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Organic Chemicals; Synovial Fluid; Tissue Distribution | 2004 |
Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile.
Topics: Adolescent; Adult; Contraceptives, Oral, Combined; Cross-Over Studies; Cyclooxygenase 2; Diclofenac; Double-Blind Method; Ethinyl Estradiol-Norgestrel Combination; Female; Humans; Isoenzymes; Membrane Proteins; Organic Chemicals; Progesterone; Prostaglandin-Endoperoxide Synthases; Sex Hormone-Binding Globulin | 2004 |
Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Humans; Ibuprofen; Middle Aged; Organic Chemicals; Peptic Ulcer; Treatment Outcome | 2004 |
Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dysmenorrhea; Female; Humans; Isoenzymes; Lactones; Membrane Proteins; Middle Aged; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Sulfones; Treatment Outcome | 2004 |
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Health Status; Humans; Ibuprofen; Isoenzymes; Membrane Proteins; Middle Aged; Naproxen; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Prognosis; Prostaglandin-Endoperoxide Synthases; Risk Factors | 2004 |
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain; Placebos; Surveys and Questionnaires; Treatment Outcome | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides | 2004 |
Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Cyclooxygenase 2; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Isoenzymes; Male; Membrane Proteins; Methotrexate; Middle Aged; Organic Chemicals; Prostaglandin-Endoperoxide Synthases | 2004 |
Lumiracoxib.
Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Half-Life; Humans; Male; Molecular Structure; New Zealand; Organic Chemicals; Osteoarthritis; Oxycodone; Pain; Pyrazoles; Sulfonamides; Terminology as Topic; World Health Organization | 2004 |
Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Naproxen; Organic Chemicals; Pain Measurement; Treatment Outcome | 2004 |
Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2005 |
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain; Pain Measurement; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.
Topics: Adolescent; Adult; Arachidonic Acid; Aspirin; Collagen; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Epoprostenol; Female; Humans; Male; Middle Aged; Organic Chemicals; Platelet Aggregation; Platelet Aggregation Inhibitors; Thromboxane B2 | 2005 |
Lumiracoxib is effective in the treatment of episodic tension-type headache.
Topics: Acute Disease; Adolescent; Adult; Aged; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Organic Chemicals; Tension-Type Headache; Treatment Outcome | 2005 |
The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Morphine; Naproxen; Organic Chemicals; Pain Measurement; Pain, Postoperative; Sample Size | 2005 |
Safety and efficacy of lumiracoxib compared with NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Diseases; Humans; Incidence; Organic Chemicals; Osteoarthritis; Risk Factors; Time Factors; Treatment Outcome | 2005 |
First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
Topics: Aged; Analgesics; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2006 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides | 2007 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis | 2007 |
Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
Topics: Abdominal Pain; Acute Disease; Administration, Oral; Adult; Aged; Analysis of Variance; Argentina; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Germany; Gout; Headache; Humans; Indomethacin; Joints; Logistic Models; Male; Middle Aged; Pain Measurement; Treatment Outcome; Vertigo | 2007 |
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Duodenal Ulcer; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Risk Factors; Risk Reduction Behavior; Stomach Ulcer | 2007 |
Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
Topics: Adolescent; Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Placebo Effect; Pyrazoles; Sulfonamides; Time Factors; Tooth Extraction; Tooth, Impacted; Treatment Outcome | 2008 |
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Statistics as Topic | 2008 |
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
Topics: Administration, Oral; Adult; Aged; Capsule Endoscopes; Cross-Over Studies; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Naproxen; Omeprazole; Probability; Reference Values; Risk Assessment; Ulcer | 2008 |
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Europe; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome; United States | 2008 |
Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dysmenorrhea; Female; Humans; Middle Aged; Naproxen; Pain Measurement; Treatment Outcome | 2008 |
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Hypertension; Ibuprofen; Middle Aged; Osteoarthritis; Treatment Outcome | 2008 |
A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Creatinine; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Pain Measurement | 2008 |
A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
Topics: Aged; Arthralgia; Blood Pressure; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Europe; Female; Gastrointestinal Tract; Humans; Incidence; Kidney; Lactones; Longitudinal Studies; Male; Middle Aged; Osteoarthritis; Sulfones | 2008 |
A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
Topics: Acute Disease; Adult; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Musculoskeletal Diseases; Naproxen; Pain; Treatment Outcome | 2008 |
[Evaluation of the analgesic effects of the lumiracoxib compared with placebo in the 24 first postoperative hours].
Topics: Adult; Analgesia; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Diclofenac; Dipyrone; Female; Humans; Pain, Postoperative; Time Factors; Tramadol | 2009 |
The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Ibuprofen; Male; Middle Aged; Osteoarthritis; Treatment Outcome | 2010 |
A double-blind, randomized clinical trial assessing the effects of a single dose of preemptive anti-inflammatory treatment in orthodontic pain.
Topics: Administration, Oral; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Facial Pain; Orthodontic Appliances; Pain Measurement; Premedication; Prospective Studies; Statistics, Nonparametric; Tooth Movement Techniques | 2011 |
A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis, Hip; Pain; Pain Measurement; Treatment Outcome | 2011 |
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Male; Middle Aged; Osteoarthritis | 2013 |
Steroidal and non-steroidal cyclooxygenase-2 inhibitor anti-inflammatory drugs as pre-emptive medication in patients undergoing periodontal surgery.
Topics: Adult; Alveolectomy; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Crown Lengthening; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dental Anxiety; Dental Plaque Index; Dexamethasone; Diclofenac; Double-Blind Method; Edema; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Pain Measurement; Pain, Postoperative; Periodontal Diseases; Periodontal Index; Postoperative Complications; Premedication; Subgingival Curettage; Surgical Flaps; Treatment Outcome | 2012 |
Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.
Topics: Adult; Arachidonic Acid; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Humans; Male; Prostaglandins; Pyridines; Sulfones; Young Adult | 2014 |
67 other study(ies) available for diclofenac and cox 189
| Article | Year |
|---|---|
Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
Topics: Amino Acid Substitution; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Kinetics; Male; Membrane Proteins; Mice; Models, Molecular; Mutation, Missense; Protein Binding; Protein Structure, Tertiary; Sheep; Time Factors | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Exploring activity cliffs in medicinal chemistry.
Topics: Computer Graphics; Data Mining; Drug Discovery; Ligands; Molecular Structure; Pharmaceutical Preparations; Structure-Activity Relationship | 2012 |
Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.
Topics: Animals; Binding Sites; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Endocannabinoids; Mice; Molecular Docking Simulation | 2013 |
Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.
Topics: Analysis of Variance; Animals; Behavior, Animal; Bone Density; Bone Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Freund's Adjuvant; Hyperalgesia; Inflammation; Isoenzymes; Isoxazoles; Organic Chemicals; Pain; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Radiology; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors; Tumor Cells, Cultured | 2004 |
Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.
Topics: Administration, Oral; Adult; Diclofenac; Feces; Humans; Male; Metabolic Clearance Rate; Middle Aged; Organic Chemicals | 2004 |
No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor.
Topics: Administration, Oral; Area Under Curve; Bilirubin; Case-Control Studies; Cyclooxygenase Inhibitors; Diclofenac; Drug Administration Schedule; Female; Half-Life; Humans; Liver Diseases; Male; Middle Aged; Organic Chemicals; Prothrombin Time; Serum Albumin; Switzerland; Tablets; Time Factors; Treatment Outcome | 2004 |
Evidence in practice--number 3: Cox 2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medicine; Humans; Ibuprofen; Middle Aged; Naproxen; Organic Chemicals; Osteoarthritis; Stomach Ulcer | 2004 |
The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Endothelin-1; Fever; Indomethacin; Injections, Intraperitoneal; Injections, Intraventricular; Intubation, Gastrointestinal; Lipopolysaccharides; Male; Organic Chemicals; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2005 |
COX-2 drug may help treat osteoarthritis.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoenzymes; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases | 2004 |
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Biological Availability; Blood Platelets; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Disease Models, Animal; Drug Evaluation, Preclinical; Edema; Female; Fever; Fibroblasts; Humans; Hyperalgesia; Male; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Rats, Wistar; Skin; Thromboxane B2 | 2005 |
Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model.
Topics: Animals; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Dose-Response Relationship, Drug; Female; Lipopolysaccharides; Organic Chemicals; Rats; Rats, Inbred Lew | 2005 |
Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib.
Topics: Analgesics; Animals; Apamin; Behavior, Animal; Charybdotoxin; Diclofenac; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Formaldehyde; Glyburide; Guanylate Cyclase; Hindlimb; Injections, Spinal; Injections, Subcutaneous; Methiothepin; Naloxone; Neurotoxins; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Organic Chemicals; Oxadiazoles; Pain; Pain Measurement; Quinoxalines; Rats; Rats, Wistar; Scorpion Venoms | 2005 |
Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Organic Chemicals; Osteoarthritis; Pain, Postoperative; Randomized Controlled Trials as Topic; Tooth Extraction; Treatment Outcome | 2005 |
Systemic inflammation induces COX-2 mediated prostaglandin D2 biosynthesis in mice spinal cord.
Topics: Animals; Blotting, Western; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Diclofenac; Immunoenzyme Techniques; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Organic Chemicals; Prostaglandin D2; Radioimmunoassay; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spinal Cord; Tumor Necrosis Factor-alpha | 2006 |
Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model.
Topics: Administration, Oral; Animals; Choroidal Neovascularization; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Fluorescein Angiography; Laser Coagulation; Male; Optic Disk; Organic Chemicals; Rats; Rats, Inbred BN | 2005 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib.
Topics: Animals; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Etoricoxib; Gene Expression Regulation; Macrophages; Mice; NF-kappa B; Nitric Oxide Synthase Type II; Nitrites; Organic Chemicals; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Pyridines; Sulfones; Transcription Factor AP-1 | 2006 |
A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma.
Topics: Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Male; Molecular Structure; Reproducibility of Results | 2006 |
COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression.
Topics: Animals; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression Regulation; Interferon-gamma; Interleukin-10; Lactones; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Sulfones; T-Box Domain Proteins; T-Lymphocytes; Time Factors | 2007 |
Examination of the interaction between peripheral lumiracoxib and opioids on the 1% formalin test in rats.
Topics: Analgesics, Opioid; Animals; Codeine; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Combinations; Drug Synergism; Female; Injections; Nalbuphine; Pain Measurement; Rats; Rats, Wistar | 2008 |
COX-2-dependent and potentially cardioprotective effects of negative inotropic substances released after ischemia.
Topics: Adenosine Triphosphate; Animals; Calcium Signaling; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Depression, Chemical; Diastole; Diclofenac; Disease Models, Animal; Glyburide; In Vitro Techniques; Indomethacin; Myocardial Contraction; Myocardial Ischemia; Myocardium; Myocytes, Cardiac; Nitrobenzenes; Perfusion; Potassium Channel Blockers; Potassium Channels; Rats; Reperfusion Injury; Research Design; Sulfonamides; Systole; Time Factors | 2007 |
Australian drugs regulator cancels registration of COX 2 inhibitor.
Topics: Australia; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Humans; Osteoarthritis | 2007 |
Advice for nurses on drug withdrawal.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Australia; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Humans; Osteoarthritis | 2007 |
COX 2 inhibitor rejected in North America but retained in Europe.
Topics: Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Europe; Humans; North America | 2007 |
[Lumiracoxib--Prexigem].
Topics: Arthritis; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Pain | 2007 |
Antagonism of thromboxane receptors by diclofenac and lumiracoxib.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cell Line; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Male; Middle Aged; Muscle, Smooth, Vascular; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane; Signal Transduction | 2007 |
[Lumiracoxib taken off the market in Australia. What does that mean for our patients? (interview by Dr. Judith Neumaier)].
Topics: Australia; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Drug and Narcotic Control; Germany; Humans; Risk Factors | 2007 |
In vitro metabolic activation of lumiracoxib in rat and human liver preparations.
Topics: Acetylcysteine; Animals; Cells, Cultured; Chromatography, Liquid; Cyclooxygenase 2 Inhibitors; Diclofenac; Hepatocytes; Humans; Microsomes, Liver; Rats; Tandem Mass Spectrometry | 2008 |
Anti-inflammatory effect of alpha, beta-Amyrin, a pentacyclic triterpene from Protium heptaphyllum in rat model of acute periodontitis.
Topics: Acute Disease; Administration, Oral; Animals; Anti-Inflammatory Agents; Burseraceae; Dexamethasone; Diclofenac; Disease Models, Animal; Gingiva; Gingivitis; Isomerism; Male; Molecular Structure; Neutrophil Infiltration; Oleanolic Acid; Oxidative Stress; Pentacyclic Triterpenes; Periodontitis; Peroxidase; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2008 |
Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Diclofenac; Docetaxel; Humans; Lung Neoplasms; Taxoids | 2008 |
Tolerability of lumiracoxib in patients with analgesic intolerance.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Middle Aged | 2008 |
Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts.
Topics: Benzoquinones; Cyclooxygenase 2 Inhibitors; Diclofenac; Glutathione; Humans; Imines; Microsomes, Liver; Peroxidases; Spectrophotometry, Ultraviolet | 2009 |
Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?
Topics: Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Humans; Monocytes | 2009 |
Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: a combination analysis study.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Facial Pain; Injections, Intraperitoneal; Male; Pain Measurement; Rats; Rats, Wistar; Receptors, Opioid, mu | 2009 |
Liquid chromatographic determination of lumiracoxib in pharmaceutical formulations.
Topics: Chemistry, Pharmaceutical; Chromatography, Liquid; Diclofenac | 2010 |
Synthesis and evaluation of a radioiodinated lumiracoxib derivative for the imaging of cyclooxygenase-2 expression.
Topics: Animals; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Iodine Radioisotopes; Isotope Labeling; Macrophages; Male; Metabolic Clearance Rate; Organ Specificity; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2009 |
Effect of COX-2 inhibitor after TNBS-induced colitis in Wistar rats.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Inflammatory Bowel Diseases; Rats; Rats, Wistar; RNA, Messenger; Trinitrobenzenesulfonic Acid | 2009 |
Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats.
Topics: Administration, Oral; Analgesics; Animals; Biological Availability; Carrageenan; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hyperalgesia; Inflammation Mediators; Models, Biological; Nonlinear Dynamics; Rats; Rats, Wistar; Time Factors | 2010 |
Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk.
Topics: Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Endothelium, Vascular; Humans; Receptors, Thromboxane A2, Prostaglandin H2 | 2010 |
A novel transdermal delivery system for the anti-inflammatory lumiracoxib: influence of oleic acid on in vitro percutaneous absorption and in vivo potential cutaneous irritation.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Diclofenac; Drug Carriers; Drug Eruptions; Oleic Acid; Skin; Skin Absorption; Swine | 2010 |
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Hyperalgesia; Inflammation; Male; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2010 |
Influence of oleic acid on the rheology and in vitro release of lumiracoxib from poloxamer gels.
Topics: Anti-Inflammatory Agents; Cellulose; Delayed-Action Preparations; Diclofenac; Drug Carriers; Excipients; Gels; Membranes, Artificial; Oleic Acid; Poloxamer; Rheology; Transition Temperature; Viscosity | 2010 |
Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats.
Topics: Acute Lung Injury; Aminopyridines; Animals; Benzamides; Bronchoalveolar Lavage Fluid; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cyclopropanes; Diclofenac; Disease Models, Animal; Humans; Inflammation; Lipopolysaccharides; Male; Neutrophil Infiltration; Phosphodiesterase 4 Inhibitors; Pyrazoles; Rats; Rats, Wistar | 2011 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Treatment of experimental periodontal disease by a selective inhibitor of cyclooxygenase-2 with scaling and root planing (SRP).
Topics: Alveolar Bone Loss; Animals; Chemotherapy, Adjuvant; Cyclooxygenase 2 Inhibitors; Dental Scaling; Diclofenac; Injections, Subcutaneous; Male; Periodontitis; Rats; Rats, Wistar; Root Planing | 2010 |
Synthesis, characterization and pharmacological evaluation of 1-(2-chloro-6-fluorophenyl)-5-methylindolin-2-one: a new anti-inflammatory compound with reduced gastric ulceration properties.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Movement; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Stability; Female; Gastric Mucosa; Hydrogen-Ion Concentration; Indoles; Indomethacin; Lactams; Male; Mice; Prodrugs; Rats; Rats, Wistar; Stomach Ulcer | 2010 |
Determination of lumiracoxib by a validated stability-indicating MEKC method and identification of its degradation products by LC-ESI-MS studies.
Topics: Chemistry, Pharmaceutical; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Diclofenac; Spectrometry, Mass, Electrospray Ionization; Tablets | 2011 |
Severe acute liver injury associated with lumiracoxib.
Topics: Acute Disease; Autoantibodies; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Fatal Outcome; Female; Humans; Liver Transplantation; Middle Aged; Osteoarthritis | 2012 |
Effect of COX-2 inhibitor lumiracoxib and the TNF-α antagonist etanercept on TNBS-induced colitis in Wistar rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Inflammatory Bowel Diseases; Male; Random Allocation; Rats; Rats, Wistar; Receptors, Tumor Necrosis Factor; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2012 |
Lessons from Lumiracoxib: are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs?
Topics: Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans | 2012 |
Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors.
Topics: Adolescent; Adult; Animals; Anti-Inflammatory Agents; Aorta; Blood Platelets; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Design; Humans; Male; Middle Aged; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane A2, Prostaglandin H2; Structure-Activity Relationship; Tetrazoles; Thromboxanes; Young Adult | 2012 |
Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Female; Formaldehyde; Injections; Injections, Spinal; Models, Biological; Nonlinear Dynamics; Pain; Pain Measurement; Rats; Rats, Wistar; Time Factors; Up-Regulation | 2012 |
Pharmacological evaluation and preliminary pharmacokinetics studies of a new diclofenac prodrug without gastric ulceration effect.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Diclofenac; Dinoprostone; Disease Models, Animal; Edema; Leukocytes; Male; Mice; Molecular Structure; Peritoneal Cavity; Prodrugs; Rats; Stomach Ulcer | 2012 |
Lumiracoxib-induced cholestatic liver injury.
Topics: Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cholestasis; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans | 2013 |
Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Design; Humans; Isoxazoles; Models, Molecular; Neoplasms; Pain; Sulfonamides | 2014 |
Effect of selective cyclooxygenase-2 inhibitor lumiracoxib on phenolsulfonphthalein disposition in rats.
Topics: Animals; Coloring Agents; Cyclooxygenase 2 Inhibitors; Diclofenac; Kidney; Male; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Phenolsulfonphthalein; Random Allocation; Rats, Wistar | 2014 |
Two-photon uncageable enzyme inhibitors bearing targeting vectors.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Lasers; Photons | 2015 |
In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adolescent; Adult; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; HEK293 Cells; Humans; Male; Middle Aged; Naphthalenes; Naproxen; Propionates; Receptors, Thromboxane; Young Adult | 2016 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |
Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Diclofenac; Mice; Mice, Inbred C57BL | 2017 |
Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.
Topics: Amoxicillin-Potassium Clavulanate Combination; Cell Adhesion Molecules; Chemical and Drug Induced Liver Injury; Diclofenac; Floxacillin; Genome-Wide Association Study; Genotype; HLA-B Antigens; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Lapatinib; Liver; Proteins; Quinazolines | 2017 |
Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diclofenac; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Genetic Predisposition to Disease; Humans; Melanoma; Mitogen-Activated Protein Kinases; Mutation; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Time Factors; Vemurafenib | 2019 |
Bioactivation of lumiracoxib in human liver microsomes: Formation of GSH- and amino adducts through acyl glucuronide.
Topics: Activation, Metabolic; Amino Acids; Biotransformation; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Diclofenac; Glucuronides; Glutathione; Humans; Isomerism; Microsomes, Liver; Tandem Mass Spectrometry | 2020 |
IL-1β and TNF-α Modulation of Proliferated and Committed Myoblasts: IL-6 and COX-2-Derived Prostaglandins as Key Actors in the Mechanisms Involved.
Topics: Animals; Cell Differentiation; Cell Line; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Interleukin-1beta; Interleukin-6; Mice; Muscle Development; Muscle, Skeletal; Myoblasts; Prostaglandins; Receptors, Interleukin-6; Regeneration; Signal Transduction; Tumor Necrosis Factor-alpha | 2020 |
A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Diclofenac; Hydroxylation; Linear Models; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |